Allopurinol Tablets

This product is a drug that inhibits the synthesis of uric acid. Allopurinol and its metabolite oxypurinol can inhibit xanthine oxidase, preventing hypoxanthine and xanthine from being metabolized into uric acid, thereby reducing the production of uric acid. It reduces the uric acid content in the blood and urine to a level below the solubility, prevents uric acid from forming crystals and depositing in joints and other tissues, and also helps to redissolve uric acid crystals in the tissues of gout patients. Allopurinol also inhibits the synthesis of new purines in the body by acting on hypoxanthine-guanine phosphate nucleic acid transferase. The blood uric acid concentration begins to decrease 24 hours after oral administration of this product, and the decrease is most obvious in 2 to 4 weeks.

Allopurinol

This product is white tablets.

Used for 1. Primary and secondary hyperuricemia, especially hyperuricemia caused by excessive uric acid production; 2. Patients with recurrent or chronic gout; 3. Tophi; 4. Uric acid kidney stones and (or) uric acid nephropathy; 5. Hyperuricemia with renal insufficiency.

Oral. 1. Common dosage for adults: initial dose is 50 mg once, 1 to 2 times a day, and can be increased by 50 to 100 mg per week to 200 to 300 mg per day, divided into 2 to 3 doses. Measure blood and urine uric acid levels every 2 weeks. If they have reached normal levels, no more increments will be made. If they are still high, they can be increased again. However, the maximum daily dose should not exceed 600 mg. 2. Common dosage for children to treat secondary hyperuricemia: 50 mg each time for children under 6 years old, 1 to 3 times a day; 100 mg each time for children aged 6 to 10 years old, 1 to 3 times a day. The dosage can be adjusted as appropriate.

1. Rash: It may be pruritic papules or urticaria. If the rash is extensive and persistent, and symptomatic treatment is ineffective and there is a tendency to worsen, the drug must be discontinued. Domestic clinical journals have reported cases of exfoliative dermatitis-type drug eruptions after taking this product. 2. Gastrointestinal reactions: including diarrhea, nausea, vomiting and abdominal pain. 3. If leukopenia, thrombocytopenia, anemia, or bone marrow suppression occur, discontinuation of the drug should be considered. 4. Other symptoms include hair loss, fever, lymphadenopathy, hepatotoxicity, interstitial nephritis and allergic vasculitis. 5. Several cases of sudden death of patients with unknown causes while taking this product have been reported abroad.

It is contraindicated for patients who are allergic to this product, have severe liver and kidney dysfunction, or have obvious low blood cells.

Precautions for children: The dosage for children should be adjusted as appropriate. Precautions for pregnancy and lactation: Forbidden. Precautions for the elderly: The elderly should use the drug with caution and reduce the daily dosage.

1. Drinking alcohol, chlorthalidone, ethacrynic acid, furosemide, metolazone, pyrazinamide or thiazide diuretics can increase the uric acid content in serum. When using this product to control gout and hyperuricemia, attention should be paid to the adjustment of dosage. For patients with hypertension or poor renal function, there are reports of renal failure and allergies when this product is used together with thiazide diuretics. 2. When this product is used together with ampicillin, the incidence of rash increases, especially in patients with hyperuricemia. 3. When this product is used together with anticoagulants such as dicoumarol and indandione derivatives, the effect of anticoagulants can be enhanced, and attention should be paid to adjusting the dosage. 4. When this product is used together with azathioprine or mercaptopurine, the dosage of the latter should generally be reduced by 1/4 to 1/3. 5. When this product is used together with cyclophosphamide, the suppression of bone marrow can be more obvious. 6. When this product is used together with uricosuric drugs, the possibility of kidney stone formation can be increased. 7. It should not be taken together with iron supplements.

Keep away from light and store in sealed container.

0.1 g

24 months

Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Guangzhou Baiyunshan Pharmaceutical General

• Founded in:

  1973-07-01

• Address:

  No. 88, Yunxiang Road, Tonghe Street, Baiyun District, Guangzhou

• Tax NO.:

  91440101714253245D

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view